Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens

Zwick, Carsten; Preuss, Klaus-Dieter; Kubuschok, Boris; Held, Gerhard; Ahlgrimm, Manfred; Bittenbring, Joerg; Schubert, Joerg; Neumann, Frank; Pfreundschuh, Michael
October 2009
Annals of Hematology;Oct2009, Vol. 88 Issue 10, p999
Academic Journal
Treatment results of mantle cell lymphomas (MCL) are not satisfactory and novel therapeutic approaches are warranted. Because “shared” tumor antigens like the group of cancer testis antigens are only rarely expressed in MCL, we applied serological analysis of antigens using recombinant expression cloning (SEREX) to a complementary DNA library derived from five cases of MCL using the sera of eight patients with MCL in order to define MCL-associated antigens that are immunogenic in these patients and might be used as vaccines for patients with MCL. Five antigens were detected by SEREX. Four of the five detected antigens (hypothetical protein FLK10233, recombining binding protein suppressor, a chromosomal sequence, and interleukin-1 receptor associated kinase) are also expressed by a wide spectrum of normal human cells, excluding their use as vaccines. In contrast, the expression of CD52, which was detected by antibodies in the serum of an MCL patient, is restricted to hematopoietic cells. Interestingly, anti-CD52 antibodies were detected in this patient before and >2 years after allogeneic transplantation, indicating that both the autologous as well as the allogeneic immune system recognized CD52. Since the anti-CD52 monoclonal antibody alemtuzumab has shown activity in MCL, a vaccine consisting of recombinant CD52 alone or combined with passive immunotherapy using alemtuzumab warrants furthers clinical and immunological evaluation in MCL.


Related Articles

  • Human antiglobulin response to foreign antibodies: therapeutic benefit? deNardo, Gerald L.; Bradt, Bonnie M.; Mirick, Gary R.; deNardo, Sally J. // Cancer Immunology, Immunotherapy;May2003, Vol. 52 Issue 5, p309 

    Immunotherapies for cancer offer attractive alternatives to conventional therapies although human anti-globulin antibody (HAGA) against the antibody (Ab) administered to the patient can be an obstacle to repeated treatment. Monoclonal antibodies (mAb), whether foreign or human in origin, have...

  • New monoclonal antibodies for non-Hodgkin's lymphoma. Leonard, J. P.; Martin, P.; Ruan, J.; Elstrom, R.; Barrientos, J.; Coleman, M.; Furman, R. R. // Annals of Oncology;Jun2008 Supplement 4, Vol. 19, piv60 

    The article discusses the clinical use of monoclonal antibodies in non-Hodgkin's lymphoma treatment. Anti-CD20 rituximab is considered as the most widely used antibody for cancer treatment. The properties of antibodies that make it effective for B cell lymphoma treatment are described. The...

  • Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab. Voigt, Mareike; Braig, Friederike; Göthel, Markus; Schulte, Alexander; Lamszus, Katrin; Bokemeyer, Carsten; Binder, Mascha // Neoplasia;Nov2012, Vol. 14 Issue 11, p1023 

    Cetuximab and panitumumab, two antibodies targeting the extracellular domain of the epidermal growth factor receptor (EGFR), are of major clinical importance particularly in the treatment of metastatic colorectal cancer. As patients may acquire resistance-mediating mutations within the...


    Introduction. Prostate specific antigen (PSA) progression is considered to be the earliest evidence of persistent or recurrent disease after primary therapy with curative intent in prostate cancer. The purpose of the study was to evaluate the predictive value of PSA progression under...

  • Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients. Yoshihiro Ohue; Hisashi Wada; Mikio Oka; Eiichi Nakayama // OncoImmunology;Nov2014, Vol. 3 Issue 11, pN.PAG 

    Immune responses to tumor antigens have been reported in cancer patients. However, the relevance of such spontaneous immune responses to the clinical course has not been studied extensively. We showed that the overall survival of patients with antibodies against NY-ESO-1 or XAGE1 (GAGED2a)...

  • Pyridoxal phosphatase is a novel cancer autoantigen in the central nervous system. BØe, A S; Bredholt, G; Knappskog, P M; Storstein, A; Vedeler, C A; Husebye, E S; Bøe, A S // British Journal of Cancer;10/18/2004, Vol. 91 Issue 8, p1508 

    Autoantibodies against many proteins are common in sera from patients with various types of cancer. These antibodies are sometimes involved in the development of conditions associated with cancer, such as paraneoplastic neurologic disorders. We used a human brain cDNA expression library and...

  • IMMUNE RESPONSES IN BREAST CANCER PATIENTS IMMUNIZED WITH AN ANTI-IDIOTYPIC ANTIBODY MIMICKING NeuGc-CONTAINING GANGLIOSIDES. Díaz, Alain; Alfonso, Mauro; Alonso, Ruby; Saurez, Gisselle; Troche, Mayelín; Catalá, Mauricio; Díaz, Rosa María; Pérez, Rolando; Vázquez, Ana María // Revista VacciMonitor (Vacunología y Temas Afines);Oct2002, Vol. 11 Issue 4, p1 

    We developed a phase I clinical trial for patients with stage III/IV breast carcinoma treated with the anti-idiotype mAb 1E10 (Ab2) specific to an Ab1 mAb (P3) able to react specifically with N-glycolyl-containing gangliosides and with antigens expressed on human melanoma and breast carcinoma...

  • Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. Kanz, Bridgette A.; Pollack, Megan H.; Johnpulle, Romany; Puzanov, Igor; Horn, Leora; Morgans, Alicia; Sosman, Jeffrey A.; Rapisuwon, Suthee; Conry, R. Martin; Eroglu, Zeynep; Johnson, Douglas B. // Journal for ImmunoTherapy of Cancer;10/18/2016, Vol. 4, p1 

    Background: Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not...

  • Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. Grizzi, Fabio; Franceschini, Barbara; Hamrick, Cody; Frezza, Eldo E.; Cobos, Everardo; Chiriva-Internati, Maurizio // Journal of Translational Medicine;2007, Vol. 5, p3 

    Despite advances in our cellular and molecular knowledge, hepatocellular carcinoma (HCC) remains one of the major public health problems throughout the world. It is now known to be highly heterogeneous: it encompasses various pathological entities and a wide range of clinical behaviors, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics